Fanghui Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fanghui Chen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chloe Shay
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory, University, Atlanta, Georgia
22 shared publications - Fan Yang
Winship Cancer Institute Emory University Atlanta Georgia USA
22 shared publications - Hancai Dan
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
22 shared publications - Liwei Lang
Medical College of Georgia, Augusta University, Augusta, Georgia. 3
22 shared publications - Nabil F. Saba
Winship Cancer Institute Emory University Atlanta Georgia USA
22 shared publications - Yamin Li
Department of Pharmacology, State University of New York, Upstate Medical University, Syracuse, NY 13210, USA
22 shared publications
Latest Publications
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Effect of IR on viability of radioresistant and parental CAL27 and HN6 cells determined by alamarBlue assays on Day 5 after IR.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Effect of IR on viability of radioresistant and parental CAL27 and HN6 cells determined by alamarBlue assays on Day 5 after IR.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Radiotherapy plays an essential role in the treatment of head and neck squamous cell carcinoma (HNSCC), yet radioresistance remains a major barrier to therapeutic efficacy. A better understanding of the predominant pathways determining radiotherapy response could help develop mechanism-informed therapies to improve cancer management. Here we report that radioresistant HNSCC cells exhibit increased tumor aggressiveness. Using unbiased proteome profiler antibody arrays, we identify that upregulation of c-Met phosphorylation is one of the critical mechanisms for radioresistance in HNSCC cells. We further uncover that radioresistance-associated HNSCC aggressiveness is effectively exacerbated by c-Met but is suppressed by its genetic knockdown and pharmacologic inactivation. Mechanistically, the resulting upregulation of c-Met promotes elevated expression of plexin domain containing 2 (PLXDC2) through activating ERK1/2-ELK1 signaling, which in turn modulates cancer cell plasticity by epithelial–mesenchymal transition (EMT) induction and enrichment of the cancer stem cell (CSC) subpopulation, leading to resistance of HNSCC cells to radiotherapy. Depletion of PLXDC2 overcomes c-Met–mediated radioresistance through reversing the EMT progress and blunting the self-renewal capacity of CSCs. Therapeutically, the addition of SU11274, a selective and potent c-Met inhibitor, to radiation induces tumor shrinkage and limits tumor metastasis to lymph nodes in an orthotopic mouse model. Collectively, these significant findings not only demonstrate a novel mechanism underpinning radioresistance-associated aggressiveness but also provide a possible therapeutic strategy to target radioresistance in patients with HNSCC.Significance:This work provides novel insights into c-Met-PLXDC2 signaling in radioresistance-associated aggressiveness and suggests a new mechanism-informed therapeutic strategy to overcome failure of radiotherapy in patients with HNSCC.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Radiotherapy plays an essential role in the treatment of head and neck squamous cell carcinoma (HNSCC), yet radioresistance remains a major barrier to therapeutic efficacy. A better understanding of the predominant pathways determining radiotherapy response could help develop mechanism-informed therapies to improve cancer management. Here we report that radioresistant HNSCC cells exhibit increased tumor aggressiveness. Using unbiased proteome profiler antibody arrays, we identify that upregulation of c-Met phosphorylation is one of the critical mechanisms for radioresistance in HNSCC cells. We further uncover that radioresistance-associated HNSCC aggressiveness is effectively exacerbated by c-Met but is suppressed by its genetic knockdown and pharmacologic inactivation. Mechanistically, the resulting upregulation of c-Met promotes elevated expression of plexin domain containing 2 (PLXDC2) through activating ERK1/2-ELK1 signaling, which in turn modulates cancer cell plasticity by epithelial–mesenchymal transition (EMT) induction and enrichment of the cancer stem cell (CSC) subpopulation, leading to resistance of HNSCC cells to radiotherapy. Depletion of PLXDC2 overcomes c-Met–mediated radioresistance through reversing the EMT progress and blunting the self-renewal capacity of CSCs. Therapeutically, the addition of SU11274, a selective and potent c-Met inhibitor, to radiation induces tumor shrinkage and limits tumor metastasis to lymph nodes in an orthotopic mouse model. Collectively, these significant findings not only demonstrate a novel mechanism underpinning radioresistance-associated aggressiveness but also provide a possible therapeutic strategy to target radioresistance in patients with HNSCC.Significance:This work provides novel insights into c-Met-PLXDC2 signaling in radioresistance-associated aggressiveness and suggests a new mechanism-informed therapeutic strategy to overcome failure of radiotherapy in patients with HNSCC.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Elevated PLXDC2 expression in radioresistant HN6 cells is mediated by c-Met-activated ERK1/2-ELK signaling.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Elevated PLXDC2 expression in radioresistant HN6 cells is mediated by c-Met-activated ERK1/2-ELK signaling.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The putative ELK1 binding sites (the sequences are in red with indicated location) on the PLXDC2 promoter region upstream of the start codon for the full-length protein.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The putative ELK1 binding sites (the sequences are in red with indicated location) on the PLXDC2 promoter region upstream of the start codon for the full-length protein.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The correlation between the expression of ELK1 and PLXDC2 genes illustrated in scatter plot from the TCGA HPV(+) HNSCC cohort (n=98).
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The correlation between the expression of ELK1 and PLXDC2 genes illustrated in scatter plot from the TCGA HPV(+) HNSCC cohort (n=98).
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Validation the expression levels of top five most upregulated genes (identified from RNA-seq) in radioresistant CAL27 (A) and HN6 (B) cells using qRT-PCR. *p<0.05; **p<0.01.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Validation the expression levels of top five most upregulated genes (identified from RNA-seq) in radioresistant CAL27 (A) and HN6 (B) cells using qRT-PCR. *p<0.05; **p<0.01.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Effect of PLXDC2 knockdown on colony formation of radioresistant CAL27 and HN6 cells determined on Day 12 following 4 Gy IR exposure
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Effect of PLXDC2 knockdown on colony formation of radioresistant CAL27 and HN6 cells determined on Day 12 following 4 Gy IR exposure
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The correlation between the expression of ELK1 and PLXDC2 genes illustrated in scatter plot from the TCGA HPV(+) HNSCC cohort (n=98).
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The correlation between the expression of ELK1 and PLXDC2 genes illustrated in scatter plot from the TCGA HPV(+) HNSCC cohort (n=98).
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Inhibitory effect of three c-Met inhibitors on c-Met phosphorylation in CAL27 cells. CAL27 cells were treated with 2.5 µM SU11274, foretinib or crizotinib for 24 hours, followed by Western blotting analysis.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Inhibitory effect of three c-Met inhibitors on c-Met phosphorylation in CAL27 cells. CAL27 cells were treated with 2.5 µM SU11274, foretinib or crizotinib for 24 hours, followed by Western blotting analysis.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The putative ELK1 binding sites (the sequences are in red with indicated location) on the PLXDC2 promoter region upstream of the start codon for the full-length protein.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The putative ELK1 binding sites (the sequences are in red with indicated location) on the PLXDC2 promoter region upstream of the start codon for the full-length protein.